Skip to main content
Top
Published in: Discover Oncology 1/2021

Open Access 01-12-2021 | Pancreatic Cancer | Research

microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7

Authors: Liang Wang, Meijun Li, Fei Chen

Published in: Discover Oncology | Issue 1/2021

Login to get access

Abstract

Dysregulation of microRNAs (miRNAs) exerts key roles in the development of pancreatic cancer (PCa). miR-26a is reportedly a tumor suppressor in cancers. However, whether miR-26a modulates PCa progression is poorly understood. Here, we found that miR-26a was down-regulated in PCa. Overexpressed miR-26a suppressed PCa cell proliferation, colony formation, and tumor stem cell properties. Mechanically, the transcription factor E2F7 is a downstream target of miR-26a. miR-26a decreased E2F7 expression through binding to the 3’-untranslated region (UTR) of E2F7. Decreased miR-26a in PCa tissues was inversely correlated with E2F7. The inhibitory effects of miR-26a in PCa were reversed by E2F7 overexpression. Consistently, the knockout of E2F7 further significantly inhibited the growth of PCa cells combined with miR-26a overexpression. Further study revealed that E2F7 bound the promoter of vascular endothelial growth factor A (VEGFA), a key factor in angiogenesis, and transcriptionally activated the expression of VEGFA. miR-26a overexpression attenuated the effects of E2F7 on VEGFA promotion. Our results uncovered the novel function of miR-26a/E2F7/VEGFA in PCa, making miR-26a a possible target for PCa treatment.
Literature
7.
go back to reference Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef
15.
go back to reference Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12:1117–25.PubMed Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12:1117–25.PubMed
26.
go back to reference Sun TY, Xie HJ, He H, Li Z, Kong LF. miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res. 2016;8:1037–46.PubMedPubMedCentral Sun TY, Xie HJ, He H, Li Z, Kong LF. miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res. 2016;8:1037–46.PubMedPubMedCentral
29.
go back to reference Zhou B, et al. MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity. Int J Clin Exp Pathol. 2017;10:11234–41.PubMedPubMedCentral Zhou B, et al. MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity. Int J Clin Exp Pathol. 2017;10:11234–41.PubMedPubMedCentral
30.
go back to reference Gong Y, et al. MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19. Am J Cancer Res. 2018;8:1030–9.PubMedPubMedCentral Gong Y, et al. MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19. Am J Cancer Res. 2018;8:1030–9.PubMedPubMedCentral
35.
go back to reference Lin EH, et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: “seed and soil” theory revisited. Gastrointestinal Cancer Res. 2008;2:169–74. Lin EH, et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: “seed and soil” theory revisited. Gastrointestinal Cancer Res. 2008;2:169–74.
Metadata
Title
microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7
Authors
Liang Wang
Meijun Li
Fei Chen
Publication date
01-12-2021
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-021-00448-z

Other articles of this Issue 1/2021

Discover Oncology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine